dasatinib

Known as: BMS dasatinib, Dasatinib [Chemical/Ingredient], N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. Phase II studies… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Activating mutations of the activation loop of KIT are associated with certain human neoplasms, including the majority of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins. To evaluate the potential role of… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?